Comprehensive Analysis On Australian Osteoporosis Drugs Market 2023 With Future Trend, Market Size, Business Growth, Top Key players, CAGR

Report Overview

The Australian Osteoporosis Drugs market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Osteoporosis (meaning 'porous bones) is a condition that causes bones to become thin, weak, and fragile. As a result, even a minor bump or accident can cause a fracture (broken bone). Such events might include falling out of a bed or chair or tripping and falling while walking. An estimated 924,000 Australians have osteoporosis, based on self-reported data from the Australian Bureau of Statistics (ABS) 201718 National Health Survey (NHS), and 20% of people aged 75 years and over have osteoporosis (ABS 2018). This definition of osteoporosis includes people who had osteoporosis or osteopenia. Osteoporosis is more common in women than men. In 201718, 29% of women aged 75 and over had osteoporosis compared with 10% of men. Older age groups also tend to be affected. The proportion of women with osteoporosis increases with age, with those 75 and over being most affected.

Market Drivers

Rising expenditure in the discovery and development of drugs to treat osteoporosis is also a major factor driving the growth of the osteoporosis drug market. The rapid pace of urbanization giving rise to unhealthy lifestyles and eating habits, which are expected to lead to a greater number of people being impacted by this disease, thereby driving the growth of the osteoporosis drug market. Rising demand for better osteoporotic care, coupled with increasing awareness about the availability of drugs for treating the disease, is pushing market players to work in the drug development area for this indication. The market players are collaborating with patient organizations, government research organizations, and academic institutes to advance their drug development activities. All these factors are expected to drive market growth in the coming years. Due to the increase in R&D investment from major players in advanced novel bisphosphonate drugs, bisphosphonates acquired the major share in the osteoporosis market. Furthermore, other factors that boost the growth of the osteoporosis drug market are a surge in the geriatric population and a rise in the adoption of sedentary lifestyles.

Major Osteoporosis Diseases

Based on disease indication, the osteoporosis drug market can be segmented into primary and secondary osteoporosis. Primary osteoporosis is the most common form of the disease and includes postmenopausal osteoporosis (type I), and senile osteoporosis (type II) and is defined as a pathological unbalancing of bone resorption and formation that leads to persistent deficits of bone mass, which ultimately translates into increased fracture susceptibility.

Secondaryosteoporosisis characterized as having a clearly definable etiologic mechanism. Secondary osteoporosisresults from specific clinical disorders that are potentially reversible. Up to 30% of postmenopausal women and 50% of men withosteoporosismay have an underlying cause. The underlying pathogenesis ofsecondary osteoporosisis often multifactorial.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/140016/

Major Players

The osteoporosis drugs market is highly competitive, and the prominent players in the market have adopted various strategies to garner maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Amgen, Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Allergan PLC, & Eli Lilly, and Company.

The Australian Osteoporosis Drugs Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Australian Osteoporosis Drugs market. This report explores all the key factors affecting the growth of the global Australian Osteoporosis Drugs market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

To Know More About COVID-19 Impact On Australian Osteoporosis Drugs Market @ https://www.prudentmarkets.com/sample-request/140016/

Market Segmentation

By Drug Class:

Based on the drug class, the osteoporosis drug market includes bisphosphonates, selective estrogenic receptor modulator, RANKL, and others. Bisphosphonates are dominating the growth of the market as these are considered the first line of osteoporosis treatment. Furthermore, drugs containing bisphosphonates help in the reduction of bone loss by decreasing osteoclast activity. Additionally, the parathyroid hormone helps in stimulating cells that form new bones hence are widely used for patients suffering from multiple fractures. The launch of new SERMs and RANKL drug class product, such as Prolia, and arzofiene increase bone mineral density are also propagating the growth of the market.

Rank ligand inhibitors are expected to grow at a lucrative CAGR during the forecast period. The high growth potential attained is a consequence of positive patient outcomes associated with rank ligand inhibitors. The positive patient outcomes can be attributed to significant improvements in bone metabolism. Other benefits of rank ligand Inhibitors such as reduced cell bone turnover and increased bone mineral density, thereby implicating high demand.

By Distribution:

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and stores, and online pharmacies. A rise in several patients visiting the hospitals for the treatment of osteoporosis, active government support towards hospital pharmacy development, and other factors are fuelling the growth of hospital pharmacies. Furthermore, the retail pharmacies and stores segment is expected to experience wider growth owing to an increase in partnership with orthopedic centers. Moreover, other distribution channels such as online pharmacies are anticipated to boost the growth owing to online drug purchases.

Major Players

The osteoporosis drugs market is highly competitive, and the prominent players in the market have adopted various strategies to garner maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Amgen, Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Allergan PLC, & Eli Lilly, and Company.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/140016/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global Australian Osteoporosis Drugs Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global Australian Osteoporosis Drugs Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Australian Osteoporosis Drugs market
Chapter 2: Exclusive Summary - the basic information of the Australian Osteoporosis Drugs Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Australian Osteoporosis Drugs
Chapter 4: Presenting the Australian Osteoporosis Drugs Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the Australian Osteoporosis Drugs market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/140016/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the Australian Osteoporosis Drugs Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.